Study Summary
This trial demonstrates the safety of the MANTA Vascular Closure Device, which uses ultrasound to guide closure of the femoral artery, in patients undergoing elective TAVR procedures.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: within 30 days
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Ultrasound Closure
1 of 1
Experimental Treatment
180 Total Participants · 1 Treatment Group
Primary Treatment: MANTA Vascular Closure Device · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is today's patient recruitment goal for this research project?
"The sponsor, Teleflex, needs to enroll 180 eligible patients from various clinical trial sites - including Washington Hospital Center in Washington, District of Columbia and Sentara Northern Virginia Medical Center in Woodbridge, Virginia - in order to complete the study." - Anonymous Online Contributor
If I'm interested in participating in this trial, how many different places can I go to?
"This study is being conducted in several hospitals, including Washington Hospital Center, Sentara Northern Virginia Medical Center, and University of Buffalo." - Anonymous Online Contributor
Are there any presently open vacancies for patients in this experiment?
"The trial is still recruiting patients, as indicated by the 8/24/2022 edit date on clinicaltrials.gov. The listing for this study was first posted on 8/9/2022." - Anonymous Online Contributor